BioNTech (BNTX) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moderna (MRNA) has outperformed BioNTech (BNTX) over the past year, gaining 618.7% versus a loss of 10.2%. Over five years, MRNA leads with a -39.4% price change compared with -61.5% for BNTX. Moderna is the larger company by market cap ($78.66 billion vs $23.16 billion), about 3.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | MRNA |
|---|---|---|
| Share price | $92.20 | $197.02 |
| Market cap | $23.16B | $78.66B |
| 1-day change | -3.20% | +0.27% |
| YTD return | +0.05% | +566.26% |
| 1-year return | -10.19% | +618.65% |
| 5-year return | -61.54% | -39.40% |
| EPS (TTM) | $-7.83 | $-7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.94B |
| Revenue growth (YoY) | — | -39.93% |
| Net income (latest FY) | — | $-2.82B |
| Gross margin | — | 55.35% |
| Operating margin | — | -158.13% |
| Net margin | — | -145.16% |
| 52-week high | $124.00 | $212.22 |
| 52-week low | $79.52 | $22.28 |
| Distance from 52-week high | -25.65% | -7.16% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +25.59% | -38.58% |
| Average volume | 1.15M | 17.44M |
| Shares outstanding | 251.20M | 399.24M |
| Employees | 7,807 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 3.4 times larger than BioNTech by market value ($78.66B vs $23.16B).
- MRNA has outperformed BNTX by 628.8 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
BNTX vs MRNA FAQ
Which is bigger, BioNTech or Moderna?
Moderna (MRNA) is larger, with a market capitalization of $78.66B compared with $23.16B for BioNTech (BNTX).
Which stock has performed better over the past year, BNTX or MRNA?
MRNA returned +618.65% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Moderna in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.